BOSTON, MA -- (MARKET WIRE) -- May 01, 2007 -- Data from two clinical trials presented today at the American Academy of Neurology (AAN) meeting suggest that an investigational once daily extended release formulation of Lamictal® (lamotrigine) is effective as add-on treatment in patients with partial epilepsy with and without secondary generalization. Lamictal XR Extended-Release Tablets are currently in development for the treatment of epilepsy. If approved, it will be the first extended release, new generation epilepsy treatment taken once-daily.
